NASDAQ : ABUS
Arbutus Biopharma Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 4.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 832.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 791.39M |
| Enterprise Value | 702.39M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 197.85M |
| Shares Outstanding | 197.85M |
| Shares Change (YoY) | +2.21% |
| Shares Change (QoQ) | +1.16% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 59.10% |
| Float | 150.64M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 5.07 |
| Forward PE | n/a |
| PS Ratio | 4.36 |
| Forward PS | 195.54 |
| PB Ratio | 3.06 |
| P/TBV Ratio | 3.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 4.59 |
| EV / Sales | 3.87 |
| EV / EBITDA | 4.76 |
| EV / EBIT | 4.76 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 81.42 |
| Quick Ratio | 81.08 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | n/a |
| Interest Coverage | 1,939.86 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 89.58% |
| Return on Assets (ROA) | 48.84% |
| Return on Invested Capital (ROIC) | 52.60% |
| Return on Capital Employed (ROCE) | 54.47% |
| Weighted Average Cost of Capital (WACC) | 8.41% |
| Revenue Per Employee | $9.56M |
| Profits Per Employee | $8.06M |
| Employee Count | 19 |
| Asset Turnover | 0.96 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -15.43% |
| 50-Day Moving Average | 4.69 |
| 200-Day Moving Average | 4.49 |
| Relative Strength Index (RSI) | 32.33 |
| Average Volume (20 Days) | 2,923,996 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 24.57M |
| Short Previous Month | 34.05M |
| Short % of Shares Out | 12.42% |
| Short % of Float | 16.31% |
| Short Ratio (days to cover) | 3.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 181.72M |
| Gross Profit | 163.92M |
| Operating Income | 147.43M |
| Pretax Income | 153.05M |
| Net Income | 153.05M |
| EBITDA | 147.47M |
| EBIT | 147.43M |
| Earnings Per Share (EPS) | $0.79 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 92.63M |
| Total Debt | 3.63M |
| Net Cash | 89.00M |
| Net Cash Per Share | $0.45 |
| Equity (Book Value) | 258.73M |
| Book Value Per Share | 1.31 |
| Working Capital | 270.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -24.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 44,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -24.63M |
| FCF Per Share | -$0.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 90.20% |
| Operating Margin | 81.13% |
| Pretax Margin | 84.23% |
| Profit Margin | 84.23% |
| EBITDA Margin | 81.15% |
| EBIT Margin | 81.13% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.21% |
| Shareholder Yield | -2.21% |
| Earnings Yield | 19.74% |
| FCF Yield | -3.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 60.54% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 29.51 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |